Retapamulin Microdialysis Feasibility Study
This study has been completed.
Information provided by (Responsible Party):
First received: March 14, 2013
Last updated: August 11, 2014
Last verified: August 2014
This feasibility study will allow for the determination of the in vivo recovery and time of dialysis to optimize a future thorough microdialysis study. This is a single session, open label study to evaluate the feasibility of microdialysis for Retapamulin in healthy subjects. Three healthy subjects will be enrolled and complete the study procedures. Subjects will be admitted to the research unit on Day 1 and three microdialysis probes will be placed in the thigh of each subject prior to the start of the microdialysis procedure. After normal saline solution infusion for 30 minutes, a Retapamulin solution will be infused for 90 minutes. Saline perfusion will occur during the washout period. Microdialysis sampling will be done for 30 minutes (during the last 30 minutes of drug perfusion) and dialysate sample collection will continue every 30 minutes for 4 hours. The approximate duration of study including follow-up is 4 days.
Skin Infections, Bacterial
Drug: Retapamulin Microdialysis
||Endpoint Classification: Pharmacokinetics Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
||A Study to Evaluate the Feasibility of Microdialysis to Determine Skin Concentrations of Retapamulin in Healthy Volunteers
Primary Outcome Measures:
- Retapamulin concentrations in the dialysate samples [ Time Frame: Single day ] [ Designated as safety issue: No ]
Retapamulin concentrations in the dialysate samples will be collected to calculate the length of time needed until disappearance of the drug in the dialysate (washout) and the percentage of drug recovered following perfusion of Retapamulin solution by microdialysis to the thigh of healthy volunteers. Microdialysis is a minimally-invasive sampling technique that is used for continuous measurement of free, unbound analyte concentrations in the extracellular fluid of virtually any tissue
Secondary Outcome Measures:
- Safety and tolerability of the microdialysis technique with perfused Retapamulin assessed by number of participants with Adverse Events (AEs) [ Time Frame: Up to 4 days ] [ Designated as safety issue: No ]
Adverse event collection and recording will begin with first dose and continue until the final follow-up visit
- Safety and tolerability of the microdialysis technique with perfused Retapamulin assessed by Laboratory parameters [ Time Frame: Single day ] [ Designated as safety issue: No ]
Laboratory parameters include: Hematology, Clinical Chemistry and additional parameters
- Safety and tolerability of the microdialysis technique with perfused Retapamulin assessed by Vital Sign measurements [ Time Frame: Single day (Pre-dose and at 7th hour Post-dose) ] [ Designated as safety issue: No ]
Vital Signs include: Systolic and Diastolic Blood Pressure and Pulse Rate. Pre-dose Vital Signs will be performed in triplicate and all other will be done in duplicate
| Study Start Date:
| Study Completion Date:
| Primary Completion Date:
||May 2014 (Final data collection date for primary outcome measure)
Experimental: Microdialysis arm
Three microdialysis probes will be placed in the thigh of each subject prior to the start of the microdialysis procedure/infusion using a microdialysis device. All subjects will receive Sodium Chloride solution perfused for 30 minutes followed by Retapamulin perfusion for 90 minutes and then Saline perfusion will occur during the washout period.
Drug: Retapamulin Microdialysis
After a 30 minutes equilibration period of the microdialysis procedure/infusion with normal saline solution, 50nanogram (ng)/mL Retapamulin injectable solution will be infused at a flow rate of 1.5 microliter/minute over a period of 90 minutes. The total dose perfused for each of the 3 microdialysis tubes will be 6.75ng.
|Ages Eligible for Study:
||18 Years to 55 Years
|Genders Eligible for Study:
|Accepts Healthy Volunteers:
Healthy as determined by a responsible and experienced physician, based on a medical evaluation including medical history, physical examination, laboratory tests. A subject with a clinical abnormality or laboratory parameters outside the reference range for the population being studied may be included only if the Investigator and the GlaxoSmithKline (GSK) Medical Monitor agree that the finding is unlikely to introduce additional risk factors and will not interfere with the study procedures. Subjects with clinically significant lab values outside the normal range should always be excluded from enrollment.
- The subject is able to understand and comply with protocol requirements, instructions and protocol-stated restrictions and is likely to complete the study as planned. Subject is willing to provide informed consent.
- Does not use medications containing Retapamulin while participating in the study.
- Male or female between 18 and 55 years of age inclusive, at the time of signing the informed consent.
- Body Mass Index within the range 18.5 to 32 kilogram/ meter^2 (inclusive).
- The following normal ranges for blood pressure and heart rate are given as a guide: Systolic blood pressure 90 to 140 milimeter of Mercury (mmHg), Diastolic blood pressure 60 to 90 mmHg, and Heart rate 45 to 100 beats per minute (bpm). The investigator may interpret screening vital sign data based on the subject's age, physical state and level of fitness. Subjects with vital sign readings marginally outside the normal range may be included in the study if in the investigator's opinion these values are not clinically significant and will not present a safety risk or affect study assessments.
- A female subject is eligible to participate if she is of non-childbearing potential (defined as pre-menopausal females with a documented tubal ligation or hysterectomy; or postmenopausal defined as 12 months of spontaneous amenorrhea [in questionable cases a blood sample with simultaneous follicle stimulating hormone > 40 milli international unit/mililiter (mL) and estradiol < 40 picogram/ml [<147 picomoles/Liter] is confirmatory]. Females on hormone replacement therapy and whose menopausal status is in doubt will be required to use one of the contraception methods) or Child-bearing potential and agrees to use one of the contraception methods for an appropriate period of time (as determined by the product label or investigator) prior to the start of dosing to sufficiently minimize the risk of pregnancy at that point. Female subjects must agree to use contraception until study completion (i.e. follow-up phone call). Male subjects with female partners of child-bearing potential must agree to use one of the contraception methods. This criterion must be followed from the time of the first dose of study medication until study completion (i.e. follow-up phone call).
- Alanine aminotransferase, alkaline phosphatase and bilirubin <= 1.5x Upper limit of normal (ULN) (isolated bilirubin >1.5xULN is acceptable if bilirubin is fractionated and direct bilirubin <35 percent).
- QT interval corrected for Heart rate (QTc), QTcB (Bazett's formula) or QTcF (Fridericia's formula) < 450 millisecond (msec); or QTc < 480 msec in subjects with Bundle Branch Block.
- Does not currently smoke cigarettes or tobacco and has not smoked within the past 12 months prior to the study.
- Does not consume alcohol 72 hours prior to the start of and during the study
- Unwillingness or inability to follow the procedures outlined in the protocol
- Subject is mentally or legally incapacitated.
- History of current significant medical illness including cardiovascular thrombotic events, myocardial infarction, stroke or other cardiac disease, hypertension, peptic ulcer disease or gastrointestinal bleeding, skin disorders, hematological disease, bronchospastic respiratory disease, asthma, diabetes mellitus, renal or hepatic insufficiency, or any other illness that the investigator deems clinically significant for exclusion of the subject from the study.
- History of sensitivity to any of the study medications, or components thereof or a history of drug or other allergy that, in the opinion of the investigator or GSK Medical Monitor, contraindicates their participation.
- History of skin conditions including atopic dermatitis, dry skin, or ichtyosis vulgaris.
- Surgical history within 3 months prior to the start of the study.
- Clinically significant acute illness 7 days prior to study start.
- Excessive hair, tattooing, scar tissue, or other tissue damage at the application site that could affect drug recovery or patient safety.
- Use of topical moisturizers (does not include facial moisturizers) 48 hours before the start of and during the study.
- Strenuous exercise 48 hours before the start of and during the study.
- Unable to refrain from the use of non-prescription drugs, including non- steroidal ant-inflammatory drugs (NSAIDS), vitamins, herbal and dietary supplements (including St John's Wort) within 7 days (or 14 days if the drug is a potential enzyme inducer) or 5 half-lives (whichever is longer) prior to the first dose of study medication, unless in the opinion of the Investigator and GSK Medical Monitor the medication will not interfere with the study procedures or compromise subject safety.
- History of regular alcohol consumption within 6 months of the study defined as an average weekly intake of >14 drinks for males or >7 drinks for females. One drink is equivalent to 12 gram of alcohol: 12 ounces (360mL) of beer; 5 ounces (150mL) of wine; or 1.5 ounce (45mL) of 80 proof distilled spirits.
- A positive pre-study drug/alcohol screen.
- Pregnant females as determined by positive serum human chorionic gonadotropin (hCG) at screening or urine hCG test prior to dosing.
- Lactating females.
- The subject has participated in a clinical trial and has received an investigational product within the following time period prior to the first dosing day in the current study: 30 days, 5 half-lives or twice the duration of the biological effect of the investigational product (whichever is longer).
- Exposure to more than four new chemical entities within 12 months prior to the first dosing day.
- Where participation in the study would result in donation of blood or blood products in excess of 500 mL within a 56 day period.
- Employees of the investigator or study center, with direct involvement in the proposed study or similar studies including family members of the employees or the investigator
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01812382
|GSK Investigational Site
|Gainesville, Florida, United States, 32610 |
||GSK Clinical Trials
No publications provided
History of Changes
|Other Study ID Numbers:
|Study First Received:
||March 14, 2013
||August 11, 2014
||United States: Food and Drug Administration
Keywords provided by GlaxoSmithKline:
Additional relevant MeSH terms:
ClinicalTrials.gov processed this record on September 18, 2014
Skin Diseases, Infectious